Compare YQ & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YQ | ATNM |
|---|---|---|
| Founded | 2012 | 2000 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.8M | 31.4M |
| IPO Year | 2020 | 2013 |
| Metric | YQ | ATNM |
|---|---|---|
| Price | $2.55 | $1.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 3.1K | ★ 233.5K |
| Earning Date | 12-08-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.17 |
| EPS | N/A | ★ 0.53 |
| Revenue | N/A | ★ $90,000.00 |
| Revenue This Year | $274.52 | $29,066.67 |
| Revenue Next Year | $29.79 | N/A |
| P/E Ratio | ★ N/A | $2.06 |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $1.68 | $0.74 |
| 52 Week High | $5.25 | $1.72 |
| Indicator | YQ | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 37.29 | 35.95 |
| Support Level | $2.44 | $0.91 |
| Resistance Level | $2.63 | $1.21 |
| Average True Range (ATR) | 0.23 | 0.14 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 2.94 | 6.11 |
17 Education & Technology Group Inc is engaged in providing education and education technology services in the People's Republic of China (PRC) with a focus on the Teaching and Learning SaaS offerings. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.